Amicus Therapeutics' GAAP loss for 9M 2021 was $167.183 million, down 18.6% from $205.451 million in the prior year. Revenue increased 17.4% to $223.36 million from $190.315 million a year earlier.
Amicus Therapeutics' GAAP loss for 9M 2021 was $167.183 million, down 18.6% from $205.451 million in the prior year. Revenue increased 17.4% to $223.36 million from $190.315 million a year earlier. 
ir.amicusrx.com
English (US) 